AOL Money & Finance

mdt posts

Feed

The week in preview: No turkey earnings from Tyson, Hormel, Cracker Barrel ...

Though the earnings season is winding down, and the coming week includes the Thanksgiving holiday in the U.S., plenty of reports are still due out. And analysts surveyed by Thomson Reuters don't seem to be expecting too many turkeys among this week's bunch.

Leading U.S. meat processor Tyson Foods Inc. (TSN), which has just named a new chief executive officer and a new chief operating officer, is expected to report fiscal fourth-quarter earnings of $0.26 per share, up from $0.14 in the same period of last year. But revenue is expected to total $6.9 billion, or 4.3% less than a year ago. The full-year forecast is for a profit of $0.25 per share (-16.7) on $26.4 billion (-3.9%) in sales.

Continue reading The week in preview: No turkey earnings from Tyson, Hormel, Cracker Barrel ...

Analyst upgrades, downgrades and initiations: CMCSA, GAME, GRMN, ETN, FO, MDT, MSO ...

Analyst upgrades:

  • Deutsche Bank upgraded Vale SA (NYSE: VALE) to Buy from Hold on expectations the company will benefit from higher realized prices. The firm raised its target on shares to $30 from $23.
  • Soleil upgraded Education Management (NASDAQ: EDMC) to Buy from Gradually Accumulate following the company's Q1 results and raised its target on shares to $34 from $32.
  • Credit Suisse upgraded Medtronic (NYSE: MDT) to Outperform from Neutral. The firm also added the stock to its Focus List and raised its target on shares to $49 from $41. Credit Suisse believes Medtronic's base business is stabilizing and the stock's risk/reward is compelling.
  • Medivation (NASDAQ: MDVN) was upgraded to Buy from Hold at Roth Capital.
  • Martha Stewart (NYSE: MSO) was upgraded to Buy from Hold at Morgan Joseph.
  • Dominion Resources (NYSE: D) was upgraded to Hold from Underperform at Jefferies.

Continue reading Analyst upgrades, downgrades and initiations: CMCSA, GAME, GRMN, ETN, FO, MDT, MSO ...

Dividend growth trio: Aflac, Medtronic and Colgate-Palmolive

"One way to build an inflation hedge into your investment cash flows is to focus on stocks that are likely to boost their dividends on a regular basis," explains dividend specialist Chuck Carlson.

In his The DRIP Investor, which focuses on blue chip companies offering dividend reinvestment programs, he notes, "Since dividends are paid with cold cash, they can't be faked. Either you pay the dividend or you don't. They can't be some figment of accounting magic." Here, he looks at three favorite blue chips with strong dividend records.

Continue reading Dividend growth trio: Aflac, Medtronic and Colgate-Palmolive

Analyst upgrades, downgrades and initiations: GOOG, HOG, NOK, SWY, WAG, WSM ...

Analyst upgrades:

  • Keefe Bruyette upgraded Intercontinental Exchange (NYSE: ICE) to Outperform from Market Perform on expectations that derivatives trading will increase in the coming quarters.
  • NutriSystem (NASDAQ: NTRI) was upgraded to Buy from Neutral by Janney Montgomery, which believes that the company's earnings have hit bottom, while the company could report better-than-expected Q1 results.
  • Harley-Davidson (NYSE: HOG) was upgraded to Outperform from Sector Perform at RBC Capital. The firm thinks the company is an early-cycle story that has significant upside potential.
  • UBS upgraded Walgreen (NYSE: WAG) to Buy from Neutral citing cost cutting efforts and slowing store growth.
  • Google (NASDAQ: GOOG) was upgraded to Buy from Hold at Benchmark Co.
  • Safeway (NYSE: SWY) was upgraded to Buy from Hold by BB&T.
  • Needham upgraded Targacept (NASDAQ: TRGT) to Buy from Hold.
  • Sierra Wireless (NASDAQ: SWIR) was raised to Buy from Hold at Jesup & Lamont.

Continue reading Analyst upgrades, downgrades and initiations: GOOG, HOG, NOK, SWY, WAG, WSM ...

Analyst upgrades, downgrades and initiations: CBRL, GAME, LO, NKE, RAIL, TGT, WMT ...

Analyst upgrades:

  • Kaufman Bros. upgraded American Superconductor (NASDAQ: AMSC) to Buy from Hold as it believes the follow-on contract from Sinovel has positive implications. The firm has a $36 price target on shares.
  • Goldman upgraded Nike (NYSE: NKE) to Buy from Neutral citing valuation, visible long-term growth, and signs of sales stabilization. The firm has a $75 target on shares.
  • Deutsche Bank upgraded Huntington Bancshares (NASDAQ: HBAN) to Buy from Hold on valuation following the recent underperformance. The firm raised its target on shares to $5.50 from $4.
  • Novartis (NYSE: NVS) was upgraded to Buy from Hold at Citigroup.
  • eHealth (NASDAQ: EHTH) was upgraded to Buy from Accumulate at ThinkEquity.
  • China Precision Steel (NASDAQ: CPSL) was upgraded to Hold from Sell at Roth Capital.

Continue reading Analyst upgrades, downgrades and initiations: CBRL, GAME, LO, NKE, RAIL, TGT, WMT ...

Earnings highlights: Burger King, Dell, Dollar Tree, J. Crew, Staples, Toll Bros. ...

Here are some highlights from last week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Burger King, Dell, Dollar Tree, J. Crew, Staples, Toll Bros. ...

Medtronic increases adjusted income, beats by a penny

Medtronic (NYSE: MDT), a manufacturer of a whole host of medical devices involved with the management of diabetes and cardiovascular disease, released its Q1 data on Tuesday. Revenues increased 6%, and adjusted earnings per share came in at 79 cents (some of the adjustments were related to restructuring and litigation issues).

The company was able to grow the adjusted-per-share bottom line by 10%. In addition, according to Reuters, Medtronic beat estimates by a penny. Shareholders should keep in mind, however, that the quarter benefited from an extra week.

Continue reading Medtronic increases adjusted income, beats by a penny

Earnings highlights: Walmart, Comcast, CVS, Sprint, Hormel, Priceline and more

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Walmart, Comcast, CVS, Sprint, Hormel, Priceline and more

Medtronic: A great play on an aging population

MedtronicShares of medical device maker Medtronic Inc. (NYSE: MDT) surged on Tuesday in an otherwise lousy market after the company said tighter cost controls and new demand for spinal implants helped it exceed Wall Street's expectations. Shares have been slipping, however, since Tuesday, from a high of $35.39 to $34.44 mid-morning Thursday.

For the quarter Medtronic earned $723 million, or 65 cents per share, on revenue of $3.49 billion.

After adjusting for in-process research and development charges of $72 million, or 6 cents per share, non-GAAP net earnings came in at $795 million, or 71 cents per share, an increase of 12% and 13%, respectively, from a year ago, and one penny ahead of Street estimates.

Continue reading Medtronic: A great play on an aging population

The week in preview: A glimmer at the end of the tunnel?

Among all the negative economic data that came out last week was a positive surprise: retail sales were higher in January. A fluke or a glimmer at the end of the tunnel? That may depend on whether we see any positive surprises arising from items on this week's economic calendar:

Continue reading The week in preview: A glimmer at the end of the tunnel?

Analyst upgrades, downgrades and initiations: GOOG, AAPL, CELG, NFLX ...

Analyst upgrades:
  • Merriman upgraded shares of Google (NASDAQ: GOOG) to Neutral from Sell as they believe consensus estimates for Q4 and FY09 are no longer too high. In addition, the firm believes Google's slowing capex spend will improve margins and their recent channel checks indicate the company's ad coverage has increased significantly during Q4.
  • Oppenheimer upgraded shares of Apple (NASDAQ: AAPL) to Outperform from Perform following yesterday's disclosures regarding Steve Jobs' health. The firm has a $135 price target on Apple shares.
  • UBS upgraded BMC Software (NYSE: BMC) to Buy from Neutral and raised its target to $31 from $28 citing easier booking comps in the March quarter.
  • YRC Worldwide (NASDAQ: YRCW) was raised to Market Perform from Underperform at Wachovia.
  • Goldman removed Hewitt (NYSE: HEW) from its Conviction Sell List.
Analyst downgrades:
  • Stephens downgraded Emergency Medical Services (NYSE: EMS) to Equal Weight from Overweight on valuation, as they believe the stock is fairly valued at current levels. The firm maintains a $39 price target.
  • Merriman downgraded Super Micro Computer (NASDAQ: SMCI) to Neutral from Buy after Super Micro pre-announced a Q2 miss to reflect the company's "challenging" outlook.
  • Baird downgraded Celgene (NASDAQ: CELG) to Neutral from Outperform citing Revlimid growth concerns following their most recent survey and potential pressures on the European business and on Thalomid.
  • Medtronic (NYSE: MDT) was lowered to Market Perform from Outperform at Leerink.
  • Intercontinental Exchange (NYSE: ICE) was cut at Goldman to Neutral from Buy.
  • Devon Energy (NYSE: DVN) was downgraded to Equal Weight from Overweight at Barclays.
Analyst initiations:
  • Merriman believes Itron (NASDAQ: ITRI) is well-positioned to benefit from the upgrade to Advanced Metering Infrastructure by tier one utilities and finds the stock attractively valued. Shares were initiated with a Neutral rating.
  • Oppenheimer assumed Jones Lang LaSalle (NYSE: JLL) with a Perform rating and expects the company's growth to slow in 2009 given global credit concerns and the economic slowdown.
  • Citigroup started Telmex (NYSE: TMX) with a Sell rating and $15 target. The firm believes the company's inability to offer 3-play services could lead to accelerated market share loss in 2009.
  • Netflix (NASDAQ: NFLX) was initiated at Janney Montgomery with a Neutral rating and $31 fair value estimate.
  • Arthur J. Gallagher (NYSE: AJG) was initiated with a Neutral rating at Piper Jaffray.
  • Jesup & Lamont assumed UTi Worldwide (NASDAQ: UTIW) with a Buy rating and $18 target.

Earnings highlights: Target, Heinz, Barnes & Noble, Pepsi, Disney and others

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Target, Heinz, Barnes & Noble, Pepsi, Disney and others

Chasing Value: Feds single source Intuitive Surgical

Yesterday, in response to Chasing Value: ISRG is falling and I'm buying I received the following comment from Beltway Greg, "You're a brave dude. Why? I've watched this stock for awhile and I worry about possible entry by other folks into the market."

Brave perhaps, even foolish on occasion, but I still think this is the time to be selectively buying equities.

To those that might be concerned about competition for Intuitive Surgical Inc (NASDAQ: ISRG) you will be interested in the following:

  • NOTICE TEXT: Department of the Army U.S. Army Medical Command MEDCOM, North Atlantic Regional Contracting Office Subject: Contract prosthetic feet and leg coverings This is a notice of the Governments intent to solicit, negotiate and award a sole source contract (Note 22) contract to Intuitive surgical for Implants based on urgency. This is not a set-aside for small business. This notice is an urgent requirement for Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307, contract number W91YTZ-09-P-0147. Parties interested in future announcements shall provide detailed information of their capabilities and certifications to clearly meet the requirements stated above.

It is possible that someday ISRG will have some competition, but there does not seem to be anything on the horizon for now. Furthermore, as the user base expands the barrier to entry increases and the cost of changing systems becomes more challenging.

The most likely scenario for competition would be if another manufacturer were to create a similar system for procedures not yet addressed by ISRG's Di Vinci robotic surgical units. Some of the potential competitors, like Johnson and Johnson (NYSE: JNJ) or Medronic (NYSE: MDT), are actually corporate partners helping to distribute the units world wide. What is most likely from my point of view is that other manufacturers will find a way to partner with ISRG to develop complimentary hardware to expand the capability of the system for more procedures to get to market faster.

Sheldon Liber is the CEO of a small private investment company and the principal for design and research at an architecture & planning firm. He writes the columns Chasing Value and Serious Money.

Medtronic (MDT) sunk by earnings miss, lower outlook

MDT logoMedtronic (NYSE: MDT - option chain) shares are way lower today after the company posted a second-quarter profit of $571 million, or 51 cents per share. The company's adjusted profit of 67 cents per share missed analysts' estimates of 71 cents per share. MDT also lowered their fiscal-2009 EPS forecast by about 3% on both the high and low ends. None of this is helping the stock today. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on MDT.

This morning, MDT opened at $34.49. So far today the stock has hit a low of $31.25 and a high of $35.48. As of 12:30, MDT is trading at $32.24, down $4.18 (11.5%). The chart for MDT looks neutral and S&P gives MDT a 3 STARS (out of 5) hold ranking.

For a bearish hedged play on this stock, I would consider a January bear-call credit spread above the $42.50 range.

Continue reading Medtronic (MDT) sunk by earnings miss, lower outlook

Options Update: Medical solution providers volatility increases; MDT, COV, ABT, SYK

Medtronic (NYSE: MDT) closed at $39.93. MDT is scheduled to report Q2 EPS on November 18. MDT November 40 straddle is priced at $3.50, December 40 is at $5.50. MDT December option implied volatility of 54 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Covidien (NYSE: COV), a medical solutions device provider, closed at $37.07. COV is scheduled to report Q4 EPS on November 17. COV November 40 straddle is priced at $4.40, December 40 straddle is priced at $6.40. COV December option implied volatility of 58 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Abbott Lab (NYSE: ABT) closed at $57.14. ABT December option implied volatility of 42 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Stryker (NYSE: SYK), a medical technology company, closed at $47.70. SYK December option implied volatility of 60 is above its 26-week average of 32 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Next Page >

Symbol Lookup
IndexesChangePrice
DJIA-14.2810,318.16
NASDAQ-10.782,146.04
S&P 500-3.521,091.38

Last updated: November 23, 2009: 02:50 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance